PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial

The Lancet

Volumn 385, Issue 9965, 2015, Pages 331-340

  Raal, Frederick J ^a   Stein, Evan A ^b   Dufour, Robert ^c   Turner, Traci ^b   Civeira, Fernando ^e   Burgess, Lesley ^f   Langslet, Gisle ^g   Scott, Russell ^h   Olsson, Anders G ⁱ   Sullivan, David ^j   Hovingh, G Kees ^k   Cariou, Bertrand ^l   Gouni Berthold, Ioanna ^m   Somaratne, Ransi ⁿ   Bridges, Ian ^o   Scott, Rob ⁿ   Wasserman, Scott M ⁿ   Gaudet, Daniel ^d  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b Metabolic and Atherosclerosis Research Center   (United States)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^f STELLENBOSCH UNIVERSITY   (South Africa)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h UNIVERSITY OF OTAGO   (New Zealand)

ⁱ LINKÖPING UNIVERSITY   (Sweden)

^j ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^k ACADEMIC MEDICAL CENTER   (Netherlands)

^l NANTES UNIVERSITY HOSPITAL   (France)

^m UNIVERSITY OF COLOGNE   (Germany)

ⁿ AMGEN INC   (United States)

^o AMGEN LTD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; EVOLOCUMAB; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BACKACHE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CONTUSION; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; ENZYME INHIBITION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; VERY ELDERLY; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; HYPERLIPOPROTEINEMIA TYPE II; METABOLISM; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84921483643     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61399-4     Document Type: Article

References (29)

1. GF Watts, S Gidding, AS Wierzbicki et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation Int J Cardiol 171 2014 309 325
2. JL Goldstein, HH Hobbs, MS Brown Familial hypercholesterolemia CR Scriver AL Beaudet WS Sly The metabolic and molecular bases of inherited disease 8th edn. 2001 McGraw Hill New York 2863 2913
3. BG Nordestgaard, MJ Chapman, SE Humphries et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society Eur Heart J 34 2013 3478 390a
4. SE Leigh, AH Foster, RA Whittall, CS Hubbart, SE Humphries Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolaemia database Ann Hum Genet 72 2008 485 498
5. HH Hobbs, MS Brown, JL Goldstein Molecular genetics of the LDL receptor gene in familial hypercholesterolemia Hum Mutat 1 1992 445 466
6. E Usifo, SE Leigh, RA Whittall et al. Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment Ann Hum Genet 76 2012 387 401
7. MA Austin, CM Hutter, RL Zimmern, SE Humphries Familial hypercholesterolemia and coronary heart disease: a HuGE association review Am J Epidemiol 160 2004 421 429
8. TL Innerarity, KH Weisgraber, KS Arnold et al. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding Proc Natl Acad Sci USA 84 1987 6919 6923
9. M Abifadel, M Varret, JP Rabès et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia Nat Genet 34 2003 154 156
10. J Vandrovcova, ERA Thomas, SS Atanur et al. The use of next-generation sequencing in clinical diagnosis of familial hypercholesterolemia Genet Med 15 2013 948 957
11. A Neil, J Cooper, J Betteridge et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study Eur Heart J 29 2008 2625 2633
12. J Versmissen, DM Oosterveer, M Yazdanpanah et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study BMJ 337 2008 a2423
13. EA Stein, L Ose, K Retterstol et al. Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia J Clin Lipidol 1 2007 280 286
14. AH Pijlman, R Huijgen, SN Verhagen et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands Atherosclerosis 209 2010 189 194
15. F Raal, R Scott, R Somaratne et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial Circulation 126 2012 2408 2417
16. C Dias, A Shaywitz, SM Wasserman et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase I studies in healthy volunteers and hypercholesterolemic subjects on statins J Am Coll Cardiol 60 2012 1888 1898
17. EA Stein, S Mellis, GD Yancopoulos et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol N Engl J Med 366 2012 1108 1118
18. MJ Koren, R Scott, JB Kim et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study Lancet 380 2012 1995 2006
19. Scientific Steering Committee on behalf of the Simon Broome Register Group Risk of fatal coronary heart disease in familial hypercholesterolaemia BMJ 303 1991 893 896
20. WT Friedewald, RI Levy, DS Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
21. Y Hochberg A sharper Bonferroni procedure for multiple tests of significance Biometrika 75 1988 800 802
22. D Quade Rank analysis of covariance J Am Stat Assoc 62 1967 1187 1200
23. MJ Koren, RP Giugliano, FJ Raal et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial Circulation 129 2014 234 243
24. DJ Blom, T Hala, M Bolognese et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia N Engl J Med 370 2014 1809 1819
25. J Besseling, I Kindt, M Hof, JJ Kastelein, BA Hutten, GK Hovingh Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers Atherosclerosis 233 2014 219 223
26. PJ Talmud, S Shah, R Whittall et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study Lancet 381 2013 1293 1301
27. B Sjouke, DM Kusters, I Kindt et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome Eur Heart J 2014 10.1093/eurheartj/ehu058 published online Feb 28.
28. FJ Raal, N Honarpour, DJ Blom for the TESLA Investigators Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial Lancet 2014 published online Oct 2. http://dx.doi.org/10.1016/S0140-6736(14)61374-X
29. Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) http://clinicaltrials.gov/ct2/show/NCT01764633 (accessed Aug 29, 2013).